Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine met the main goal in a late-stage study.

Patients treated with the drug, fremanezumab, experienced a statistically significant reduction in the number of monthly headache days over the 12-week period for both monthly and quarterly dosing regimens, the company said.